Santhera to Report Half-Year 2016 Financial Results on Tuesday, September 6, 2016

Santhera Pharmaceuticals Holding AG / Santhera to Report Half-Year 2016 
Financial Results on Tuesday, September 6, 2016 . Processed and 
transmitted by Nasdaq Corporate Solutions. The issuer is solely 
responsible for the content of this announcement. 
 
   Liestal, Switzerland, August 29, 2016 - Santhera Pharmaceuticals (SIX: 
SANN), a Swiss specialty pharmaceutical company, will announce the 
financial results for the first half-year 2016 on Tuesday, September 6, 
2016, at 7:00 am CET. An Investor Conference Call with Thomas Meier, PhD, 
CEO of Santhera Pharmaceuticals, will be held on the same day at 5:00 pm 
CET. 
 
   Participants can call the following numbers 10-15 minutes before 
Conference's schedule (no code needed): 
 
   [phone] (Europe) 
 
   [phone] (UK) 
 
   [phone] (USA) 
 
   About Santhera 
 
   Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical 
company focused on the development and commercialization of innovative 
pharmaceutical products for the treatment of orphan mitochondrial and 
neuromuscular diseases. Santhera's lead product Raxone(R) is authorized 
in the European Union, Norway, Iceland and Liechtenstein for the 
treatment of Leber's hereditary optic neuropathy (LHON). For Duchenne 
muscular dystrophy (DMD), the second indication for Raxone(R) , Santhera 
has filed a Marketing Authorization Application (MAA) in the European 
Union. Santhera develops Raxone(R) in a third indication, primary 
progressive multiple sclerosis (PPMS), and omigapil for congenital 
muscular dystrophy (CMD), all areas of high unmet medical need. For 
further information, please visit the Company's website 
www.santhera.com. 
 
   Raxone(R) is a trademark of Santhera Pharmaceuticals. 
 
   For further information, contact: 
 
   Thomas Meier, PhD, Chief Executive Officer          Christoph Rentsch, 
Chief Financial Officer 
 
   Phone [phone]                                        Phone +41 
61 906 89 65 
 
   [e-mail] 
[e-mail] 
 
   Daniel Piller, Head Communications 
 
   Phone [phone] 
 
   [e-mail] 
 
   US investor contact                                             US 
Public Relations contact 
 
   Hans Vitzthum, LifeSci Advisors, LLC                    Deanne Eagle, 
Planet Communications 
 
   Phone [phone]                                         Phone +1 
917 837 5866 
 
   [e-mail] 
[e-mail] 
 
   Disclaimer / Forward-looking statements 
 
   This communication does not constitute an offer or invitation to 
subscribe for or purchase any securities of Santhera Pharmaceuticals 
Holding AG. This publication may contain certain forward-looking 
statements concerning the Company and its business. Such statements 
involve certain risks, uncertainties and other factors which could cause 
the actual results, financial condition, performance or achievements of 
the Company to be materially different from those expressed or implied 
by such statements. Readers should therefore not place undue reliance on 
these statements, particularly not in connection with any contract or 
investment decision. The Company disclaims any obligation to update 
these forward-looking statements. 
 
   # # # 
 
   News Release Schedule HY Results: 
http://hugin.info/137261/R/2037720/759306.pdf 
 
   This announcement is distributed by Nasdaq Corporate Solutions on behalf 
of Nasdaq Corporate Solutions clients. 
 
   The issuer of this announcement warrants that they are solely 
responsible for the content, accuracy and originality of the information 
contained therein. 
 
   Source: Santhera Pharmaceuticals Holding AG via Globenewswire 
 
   --- End of Message --- 
 
   Santhera Pharmaceuticals Holding AG 
 
   Hammerstrasse 49 Liestal Switzerland 
 
   ISIN: CH0027148649; 
 
 
  http://www.santhera.com 
 

(END) Dow Jones Newswires

August 29, 2016 01:00 ET (05:00 GMT)